^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    simvastatin

    i
    Other names: L-644128-000U, MK-733
    Company:
    Generic mfg.
    Drug class:
    HMG-CoA reductase inhibitor
    Related drugs:
    2d
    T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer (clinicaltrials.gov)
    P2, N=36, Recruiting, Medical University of South Carolina | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    simvastatin
    3d
    Paeonol alleviates atherosclerosis by inhibiting CD8+ T-cell activation via targeting the SYK/NFATc1 signaling pathway in ApoE-/- mice. (PubMed, J Ethnopharmacol)
    SYK in CD8+ T-cells represents a potential therapeutic target for atherosclerosis. Pae inhibits atherosclerosis by blocking the SYK/NFATc1 pathway to reduce cytotoxic mediator release and prevent vascular endothelial cell injury.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • SYK (Spleen tyrosine kinase) • GZMB (Granzyme B) • APOE (Apolipoprotein E) • NFATC1 (Nuclear Factor Of Activated T Cells 1)
    |
    simvastatin
    4d
    Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    simvastatin
    5d
    Integrated transcriptomics and molecular docking identify hub genes and statin regulators in Helicobacter pylori-associated gastric mucosal pathogenesis. (PubMed, Front Cell Infect Microbiol)
    To explore potential therapeutic interventions, we performed small-molecule drug prediction and molecular docking for hub genes revealed: Simvastatin: Linked to CCL20, NFKBIA, and ICAM1. Atorvastatin: Associated with CDKN1A, ICAM1, and TNF. TPCA-1: Targeting JAK1. These findings provide a theoretical foundation for further investigation into the molecular mechanisms underlying H. pylori-related diseases.
    Journal
    |
    BRCA1 (Breast cancer 1, early onset) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • BIRC3 (Baculoviral IAP repeat containing 3) • JAK1 (Janus Kinase 1) • TNFAIP3 (TNF Alpha Induced Protein 3) • CCL20 (C-C Motif Chemokine Ligand 20) • ICAM1 (Intercellular adhesion molecule 1) • IRF1 (Interferon Regulatory Factor 1) • ITGAM (Integrin, alpha M) • SPI1 (Spi-1 Proto-Oncogene) • ETS1 (ETS Proto-Oncogene 1) • IL17A (Interleukin 17A) • STAT1 (Signal Transducer And Activator Of Transcription 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • NFKB2 (Nuclear Factor Kappa B Subunit 2) • NFKBIA (NFKB Inhibitor Alpha 2) • NFKBIE (NFKB Inhibitor Epsilon) • TRAF1 (TNF Receptor Associated Factor 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • E2F1 (E2F transcription factor 1) • EGR1 (Early Growth Response 1) • HSF1 (Heat Shock Transcription Factor 1) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit)
    |
    simvastatin • atorvastatin
    11d
    Transcriptional and Pathway Level Heterogeneity in Luminal A Breast Cancer: A Framework for Precision Therapy. (PubMed, Arch Med Res)
    Our integrative multi-omics analysis reveals the complex molecular architecture of Luminal A breast cancer, characterized by transcriptional and pathway-level heterogeneity. The findings advocate for subtype-specific therapeutic interventions targeting transcription factor networks, redox balance, and the tumor microenvironment. This systems-level framework provides a foundation for precision risk stratification and treatment optimization in Luminal A breast cancer.
    Journal
    |
    CEBPA (CCAAT Enhancer Binding Protein Alpha) • SOX2 • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • TLX1 (T Cell Leukemia Homeobox 1)
    |
    HR positive
    |
    dexamethasone • simvastatin
    13d
    SELE is associated with reduced breast cancer susceptibility: Evidence from Mendelian randomization and single-cell transcriptome. (PubMed, Transl Oncol)
    This study provides robust genetic evidence for the causal roles of SELE, CDH1, and ALPI in reducing BC risk. The integrative proteomic-genetic-transcriptomic approach identifies potential therapeutic targets and offers new insights into BC pathogenesis, presenting hypotheses for clinical validation.
    Journal
    |
    CDH1 (Cadherin 1)
    |
    simvastatin
    23d
    Stress-Inducible Transcription Factor NUPR1 Is Involved in the Inhibitory Effects Exerted by Statins on Insulin Action in ER-Positive Breast Cancer Cells. (PubMed, Cells)
    In this study, we investigated the effects of simvastatin, atorvastatin and rosuvastatin in BC cells stimulated by insulin. Consistent with these findings, survival analyses of large cohorts of patients revealed that high levels of NUPR1 are associated with poor BC prognosis. Overall, our results provide novel mechanistic evidence supporting the repositioning of statins in BC, particularly in tumors characterized by elevated IR expression and activity.
    Journal
    |
    ER (Estrogen receptor) • IR (Insulin receptor)
    |
    ER positive
    |
    simvastatin • atorvastatin
    23d
    Targeting HIF-2α in Colorectal Cancer Reveals a Cholesterol Biosynthesis-Dependent Ferroptotic Vulnerability. (PubMed, bioRxiv)
    Targeting this pathway with clinically approved statins (atorvastatin, pitavastatin, simvastatin) synergized with PT2385 to suppress CRC cell growth, reduce colony formation, and enhance cell death...These effects are fully reversed by the ferroptosis inhibitor liproxstatin-1...In vivo, co-administration of PT2385 and atorvastatin significantly reduced tumor growth and increased ferroptotic cell death in xenografts, confirming the mechanistic link. Collectively, these findings uncover a metabolic vulnerability of CRC to dual HIF-2α and cholesterol biosynthesis inhibition, supporting a clinically actionable strategy that leverages safe, FDA-approved statins to potentiate HIF-2α-targeted therapy.
    Journal
    |
    EPAS1 (Endothelial PAS domain protein 1)
    |
    simvastatin • MK-3795 • atorvastatin • liproxstatin-1 • pitavastatin
    28d
    Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=29, Recruiting, Tongji Hospital
    New P1/2 trial
    |
    cisplatin • gemcitabine • simvastatin • AiRuiLi (adebrelimab)
    1m
    Blumea balsamifera (L.) DC. and Sargassum aquifolium J. Agardh extracts as anti-atherosclerotic, anti-inflammatory, and hepatoprotective agents in Wistar rats induced by a high-cholesterol diet. (PubMed, Open Vet J)
    The negative control was a high cholesterol diet, and the positive control was simvastatin...A decrease in AST and ALT levels was shown by administering BBLE+SAE, and a higher mean hepatocyte cell count was observed compared to the other groups. Administration of BBLE+SAE acts as an anti-atherosclerotic and hepatoprotective agent for the liver through reducing pro-inflammatory cytokines, and its use was promising for clinical studies.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • APOE (Apolipoprotein E)
    |
    simvastatin
    1m
    Exploratory Clinical Trial of 2% Simvastatin Versus 2% Simvastatin/2% Cholesterol Cream in the Treatment of Disseminated Superficial Actinic Porokeratosis (ChiCTR2600117720)
    P=N/A, N=24, Not yet recruiting, Dermatology Hospital of Southern Medical University; Dermatology Hospital of Southern Medical University
    New trial
    |
    simvastatin
    1m
    A randomized, double-blind, placebo-controlled clinical exploration of simvastatin in the treatment of lipid metabolism disorders complicated with depression (ChiCTR2500112180)
    P=N/A, N=210, Not yet recruiting, Affiliated Mental Health Center & Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine; Affiliated Mental Health Center &amp
    New trial
    |
    simvastatin